Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMBS dark side watch. Looking at .11 as next resistance point.
Today:
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences.
Mr. Michael Moffat, Cavendish co-founder and President explains, “Brain disorders affect more than 60 million Americans, that’s more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer’s disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to $1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer’s and Parkinson’s disease.” Moffat emphasizes, “Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen.”
From a PR in March:
Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
Download PDF
SAN FRANCISCO, March 10, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTC:AMBS) (Amarantus or the Company), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced today that it has closed on its previously announced Warrant Solicitation, which the Company elected to increase in size from $3.0M to $3.6M due to oversubscriptions. Concurrently, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. LPC initially purchased 4.0 million shares of Amarantus' common stock at $0.10 per share for $400,000 and has committed to invest, at the sole option of Amarantus, up to an additional $19.6M of equity capital over the term of the purchase agreement. The total gross proceeds to the Company from these two transactions upon closing is $4M.
"The capital raised through our Warrant Solicitation and the access to capital from LPC increases our flexibility to achieve a number of key milestones for the Company, including commercializing our LymPro Blood Test for Alzheimer's disease, advancing the clinical testing of Eltoprazine into late-stage development and filing one or more INDs for MANF in orphan indications," said Gerald E. Commissiong, President & CEO of Amarantus. "Going forward, the Company can focus on executing its clinical development plan, commercialization strategy and intellectual property aggregation strategy, while maintaining a strong negotiating position with potential partners due to the improved access to capital this agreement provides."
During the 30-month term of the purchase agreement the Company, at its sole discretion, has the right to sell to LPC up to an additional $19.6 million of its common stock, in amounts as described in the agreement and subject to certain conditions, which include the effectiveness of a registration statement with the U.S. Securities and Exchange Commission (SEC) covering the sale of the shares that may be issued to LPC. The Company controls the timing and amount of any future investment and LPC is obligated to make purchases, if and when the Company decides in accordance with the agreement.
There are no upper limits to the price LPC may pay to purchase Amarantus common stock and the purchase price of the shares related to any future investments will be based on the prevailing market prices of the Company's shares immediately preceding the notice of sale to LPC. LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock. In consideration for entering into the agreement and the initial investment, the Company has issued shares of common stock to LPC as a commitment fee. The agreement may be terminated by the Company at any time, at its sole discretion, without any monetary cost. The proceeds from this investment will be used for product development, commercialization and general corporate purposes.
A more detailed description of the agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC which the Company encourages be reviewed carefully.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
I have two plays I would like your opinion on please: YOD and MELY
I like that...need a like button
An observation, today marks the one month period since the last news on anything other than a conference, or a filing.
Get ready for the news express. 17 trading days left in the quarter, and first half of year.
That I agree with. Not this week though. My answer to the posters question stands as my projections.
So are you saying that you expect the price to reach $.50 this week? That is the question to which I was responding to and to my reasoning of why.
Good theory and theory noted. I don't think this action is from them. I think this is purely a trading group acting in concert to take advantage of the technicals and weak selling pressure.
As for a big jump because of your theory, yes it is possible, and likely if they are behind this. However, won't they hit their target anyway with the news that is expected?
Good discussion JP!
Do you think LPC is buying shares in the open market?
LOL...At this point they wouldn't. I am still astonished management has not tried to prop up the price and support it with some sort of PR. Still very strange, especially for a sub-penny trading company.
I doubt we hit .20 this week without news; however, if the right news is released then yes. I think tomorrow we test the .107 - .11 range without news and with news we test the .13 - .14 range, unless it is significant news. News trumps all TA.
I am telling you, someone is really trying to push this to a much higher close. These 4,999 and 9,999 trades is a sure signal of intentional run up.
Our 9,999 trading group is back on the bid slapping. I think it means they want it higher too before they begin dumping their shares.
I expect us to close around .105 - .107
Just my guess.
I would look for the last half hour to be interesting. Several who sold and expected a drop back to .08-.09 won't want to be in the sideline with news potential in the morning. Those on the sidelines are closely watching, and will chase after news to make it even more explosive.
We are moments away from some chasing mode.
teens here we come...today! This could explode into low teens with the right breakout.
Every single one is a bid slap too. Just under the 10k bid. Followed up with a few smaller trades. Seems like a trading group maybe trying to push this up?
Some very odd trading volumes and amounts coming through on level 2
I have heard about DD Amanda before but I don't remember exactly the focus of that particular scan. Could you enlighten the board of its features.
Low, have you relied on any scans for plays or just finviz?
Check out the weekly as well. I think you will find it even more explosive. I am on my phone so it isn't as easy to post the chart for all to see.
Welcome to the board fellow indy resident. I reside just west of the city myself.
Capacity "will" be an issue for production so FDA will have to approve more sites!
This test will be the good standard that leads the market.
I like the confidence.
$1000-$1500 per test
Low - FYI, AMBS broke thru the .09 resistance point at the end of day today. I had to make a day trip to Chicago for meetings all day and got the pleasant surprise this evening.
Look for the rest of the week to be flat to down a little down. Next week I expect a little more of a pr campaign to start emerging. The next two weeks should be very interesting TA wise.
If you wait and look for the PR campaign emerge, you will be too late. (Don't mean you tyfoid, just in general)
AMBS is about to explode. Just watch and see!
Definitely more people trying to short instead of buy. Other than the longs holding there likely isn't any new investor capital coming in to support even these levels. At least none evident on the bid.
This thing is primed and ready for a major pop!
The more people that take notice of AMBS the more explosive of a move. There are many on the sidelines waiting for the next technical breakout, so u r correct about the buying v. Bid.
Although, I do expect a down day or two before the next big wave up.
“Subcontractor” (1) means any person, other than the prime contractor, who offers to furnish or furnishes any supplies, materials, equipment, or services of any kind under a prime contract or a subcontract entered into in connection with such prime contract; and (2) includes any person who offers to furnish or furnishes general supplies to the prime contractor or a higher tier subcontractor.
http://acquisition.gov/far/current/html/Subpart%203_5.html
That is the point, I think that things are happening to develop this company. It is evident with the last military demos. That doesn't happen by accident, and from a 'I don't care' leader.
Clearly more has to be going on that we don't know.
Please share the actual date and time when you hear back!
I agree! That is why I am perplexed as to why they are not sharing more of their plan and/or more of their efforts/activities.
Earlier in March 2014, news broke of an Alzheimer s blood test in development through collaboration of Georgetown University and the University of Rochester. The story received considerable media attention, reporting up to 90% accuracy in a 54-patient early-stage trial. Study authors called the results a potential game-changer and the holy grail of Alzheimer s diagnosis. The media attention is clearly positive for Amarantus, as we believe LymPro, the company s own blood test, is both ahead of the test in development at GU/UR in stage and efficacy. Results from the 88-patient Phase 1 study, published in Neurobiology of Aging (Volume 33, Issue 2), show sensitivity up to 91% and specificity up to 92% for LymPro, with an overall accuracy rate of 95%.
I agree with the last sentence of this paragraph as well:
This data demonstrated that CD69 was in fact a valid biomarker for diagnosis in the blood. In addition, the company has had a number of posters selected for presentation at the Alzheimer s Association International Conference in Copenhagen in July 2014. This is especially important, as gaining traction in the scientific community is vital to the company as they seek their first customers in the clinical trial setting. We think this could be a big driver of the stock once the data is presented.
Have not heard anything from u for some time Nils, hope all is well.
That can only last for so long especially when his holdings dwindle, I mean tank, daily.
Zero times ten million is still zero!
I know she is an attorney and I know she is good. That is still no reason to continue associating with a failing company, that is if it really is failing behind the scenes.
I use to have two attorneys that worked for me in one of my companies, and both when hired on were allowed to continue their private practices.
Don't you even find it odd they are not trying to support the price with any kind of pump pr. They have not pumped this in a long time. Seems odd unless they are intentionally trying to tank this for some reason!
Funny how we had the same thought at the same time, risk.
The only thing I keep telling myself is, would Glenn tarnish his resume with a failure like this? This could be career ending for someone like himself, at least to the levels of his 'prior' job achievements.
Further, he could have bailed at any time, but has not...yet, at least. I find this the most interesting of all. What does he really have planned and know behind the scene that is keeping him there.
The same can be said with Barbara. Can someone do some searching to see if she comes up as a licensed attorney in FL, or which states she still has an active license? Also, does she appear on any other cases within those states for anyone else?
It is possible, both could be working for other companies drawing additional income and we wouldn't know it. I suspect this is the case, we just have to dig and find out.
I am gone on vacation and don't have my login info for pacer. Just some thoughts.
Talks about a rs are premature IMO. I think we should be focused on a higher stock price to keep from further dilution when draws are taken toward the $19.6 mill draw remaining.
Regardless, a natural higher share price will only help all of these issues!